Not a long ago, we saw that we'd better follow significant insider buyings when Adobe's executive bought company's shares right before the earnings. That was a significant buying because he increased his position by 30%. Here is Medivation, Senior Vice President increased his position by almost 30% as well:Andrew Kenneth Powell, SVP of Medivation, recently acquired 9,300 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on February 18, 2016. Powell now owns 29,930 shares of the company. The company itself is performing really good. Usually such companies as MDVN becomes a good acquisition target, because they are cheap enough and have a strong portfolio of 1-3 brands and some significant developments in a particular field. MDVN has 1 commercial product - XTANDI, but they have a huge portfolio of cancer-trearment products. Such products aimed to treat breast cancer, prostate cancer and some other types of this disease. I am not a professional in this field, but MDVN definitely looks good in their field. Just take a look: their revenue increased from $273M in 2013 to $943M in 2015 with just one product. Last year the company's operating profit and net income was at a very high level for such an early stage pharmaceutical company. So I think you'd better take a look at their portfolio and check some reports, if you have a special biotechnological knowledge. It seems to be a good stock to invest in.